Petrelintide Phase 2 Win Changes The Bull Case For Zealand Pharma Stock

• Zealand Pharma reported positive topline Phase 2 results for petrelintide in adults with overweight or obesity and type 2 diabetes, with up to 9.2% mean weight loss, meaningful HbA1c reductions, and a tolerability profile largely comparable to placebo.
• The decision by Zealand Pharma and Roche to move petrelintide into a large Phase 3 program signals heavier investment into chronic weight management and broader cardiometabolic indications. The trial design is already targeting obesity, diabetes, and established cardiovascular disease populations.
• The focus now shifts to how Zealand Pharma's investment narrative evolves as petrelintide enters a Roche partnered Phase 3 obesity program.

Scan a curated set of cardiometabolic peers by jumping to 127 healthcare AI stocks as you assess how Zealand Pharma fits into this fast-moving treatment theme.

Zealand Pharma Investment Narrative Recap

To own Zealand Pharma, you need to believe its peptide and amylin platform, led by petrelintide, can offset pressure on revenue and earnings that analysts currently expect to trend down over the next three years. The sharp share-price decline over the past year shows how dependent sentiment is on clinical and partnership execution rather than current profit levels.

Right now the key near term catalyst is successful execution of the petrelintide Phase 3a obesity and diabetes program with Roche, including clean full ZUPREME 2 data at a major conference. The biggest risk is clear. Any setback in late stage trials or weaker differentiation versus larger obesity competitors could prolong high R&D spend, while royalty style income from partners limits margin expansion.

The freshest operational trigger is the start of the three Phase 3a ZUPREME trials for petrelintide with Roche, which follow the positive ZUPREME 2 result in type 2 diabetes. Those studies extend Zealand Pharma's reach across obesity without diabetes, obesity with diabetes, and obesity with established cardiovascular disease, which concentrates execution risk but also focuses the story.

This program now anchors the medium term outlook, since milestone and future royalty streams are heavily tied to whether petrelintide can move smoothly through these pivotal studies and then into real world use. Alongside that, the recently opened Cambridge research hub adds another layer of fixed cost and scientific ambition, which only pays off if the pipeline beyond petrelintide also converts into later stage assets.

Zealand Pharma Consensus Forecasts in Context

Zealand Pharma's narrative projects DKK 1.9 billion revenue and DKK 367.5 million earnings by 2029. This assumes a 25.8% yearly revenue decline and an earnings decrease of about DKK 2.3 billion from DKK 2.7 billion today.

Discover why Zealand Pharma's fair value suggests a potential 75% upside to its current price before the market adjusts.

Exploring Other Perspectives

Some readers will focus on a different catalyst. The most pessimistic analysts worried that petrelintide might still struggle for pricing power, and were modeling just DKK 152.9 million of revenue and DKK 27.9 million of earnings by 2029. Those views pre date the new ZUPREME 2 data, so opinions may evolve as fresh evidence lands.

Explore 2 other Zealand Pharma fair value estimates, including one that suggests it could be worth just DKK 408.36!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zealand Pharma research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Zealand Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Zealand Pharma's overall financial health at a glance.

Looking For More Ideas Beyond Zealand Pharma?

If the Zealand Pharma story has sharpened your thinking about risk, reward, and timing, it can be useful to line it up against other opportunities that fit different checklists. A broad view across sectors and styles often helps you decide where this stock really belongs in your own shortlist.

• If you want potential mispricing with fundamentals in mind, start with a curated set of companies flagged as 174 high quality undervalued stocks to see which ones merit a closer look.
• If capital preservation and balance sheet strength sit at the top of your priorities, filter for businesses with resilient finances using the list of solid balance sheet and fundamentals (204 results).
• If you are hunting for future leaders before they are widely followed, scan the 618 high quality undiscovered gems and see which smaller stocks line up with your risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com